New psoriasis drug shows promise in early trial
NCT ID NCT03025542
Summary
This study tested an investigational drug called bimekizumab in adults with moderate to severe plaque psoriasis. The main goals were to see how well it cleared skin symptoms, how the drug behaved in the body, and if it was safe. Forty-nine participants received the drug and were monitored for up to 36 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ps0016 101
Melbourne, Australia
-
Ps0016 102
Kogarah, Australia
-
Ps0016 104
Woolloongabba, Australia
-
Ps0016 201
Ajax, Canada
-
Ps0016 202
Windsor, Canada
-
Ps0016 203
London, Canada
-
Ps0016 501
Chisinau, Moldova
-
Ps0016 704
Bexley, Ohio, United States
Conditions
Explore the condition pages connected to this study.